Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214982 | 1.00 | MLYCD (0.60) | MLYCDNAMPTHDAC1HDAC2NPC1 | |
| SCHEMBL17865780 | 0.85 | MLYCD (0.77) | MLYCDNAMPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16963429 | 0.85 | MLYCD (0.49) | MLYCDHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL16996774 | 0.85 | MLYCD (0.49) | MLYCDHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL16963427 | 0.85 | MLYCD (0.49) | MLYCDHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL19938019 | 0.81 | MLYCD (0.67) | MLYCDNAMPTHDAC1HDAC2NPC1 | |
| SCHEMBL22265984 | 0.80 | HDAC1 (0.70) | MLYCDHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL22265982 | 0.80 | HDAC1 (0.70) | MLYCDHDAC1HDAC2NPC1RAB9A | |
| SCHEMBL5687748 | 0.79 | MLYCD (0.69) | MLYCDNAMPTHDAC1HDAC2NPC1 | |
| SCHEMBL12243059 | 0.79 | MLYCD (0.69) | MLYCDHDAC1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | MLYCD 2637/4885NAMPT 559/4885HDAC1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.